Skip to main content
Premium Trial:

Request an Annual Quote

Invisible Sentinel, Victory Brewing to Develop Assay for Better Beer

NEW YORK (GenomeWeb) – Food and beverage molecular testing firm Invisible Sentinel and Victory Brewing today announced a partnership to improve beer production.

The companies will develop an assay based on Invisible's Veriflow technology to detect microbes that can compromise beer quality. Specifically, the assay, called Veriflow brewPAL, is being developed for the rapid, on-site detection of Pediococcus and Lactobacillus, which produce lactic acid and affect beer taste.

The partners said that current methods of detecting the bacteria are "laborious and time-consuming" and can delay the implementation of corrective measures. In turn, that can result in brew spoilage, higher production costs, and delayed product release. The agreement, they added, is expected to result in a Veriflow assay that will be made available internationally.

Invisible and Jackson Family Wines announced a partnership earlier this year to develop an assay to detect the yeast Brettanomyceswhich can cause a wretched aroma and taste in wine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.